Logo image of ITOS

ITEOS THERAPEUTICS INC (ITOS) Stock Fundamental Analysis

NASDAQ:ITOS - Nasdaq - US46565G1040 - Common Stock - Currency: USD

10.17  +0.19 (+1.9%)

After market: 10.17 0 (0%)

Fundamental Rating

4

ITOS gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 559 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ITOS as it has an excellent financial health rating, but there are worries on the profitability. ITOS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year ITOS has reported negative net income.
ITOS had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: ITOS reported negative net income in multiple years.
In the past 5 years ITOS reported 4 times negative operating cash flow.
ITOS Yearly Net Income VS EBIT VS OCF VS FCFITOS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

1.2 Ratios

With a decent Return On Assets value of -19.57%, ITOS is doing good in the industry, outperforming 78.53% of the companies in the same industry.
The Return On Equity of ITOS (-22.77%) is better than 83.18% of its industry peers.
Industry RankSector Rank
ROA -19.57%
ROE -22.77%
ROIC N/A
ROA(3y)-7.87%
ROA(5y)-2.39%
ROE(3y)-9.26%
ROE(5y)-0.48%
ROIC(3y)N/A
ROIC(5y)N/A
ITOS Yearly ROA, ROE, ROICITOS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

ITOS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ITOS Yearly Profit, Operating, Gross MarginsITOS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

8

2. Health

2.1 Basic Checks

ITOS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ITOS has more shares outstanding
Compared to 5 years ago, ITOS has more shares outstanding
There is no outstanding debt for ITOS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ITOS Yearly Shares OutstandingITOS Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ITOS Yearly Total Debt VS Total AssetsITOS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

ITOS has an Altman-Z score of 2.45. This is not the best score and indicates that ITOS is in the grey zone with still only limited risk for bankruptcy at the moment.
ITOS has a Altman-Z score of 2.45. This is in the better half of the industry: ITOS outperforms 71.56% of its industry peers.
ITOS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.45
ROIC/WACCN/A
WACC9.5%
ITOS Yearly LT Debt VS Equity VS FCFITOS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

ITOS has a Current Ratio of 12.62. This indicates that ITOS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 12.62, ITOS belongs to the top of the industry, outperforming 84.26% of the companies in the same industry.
ITOS has a Quick Ratio of 12.62. This indicates that ITOS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 12.62, ITOS belongs to the top of the industry, outperforming 84.26% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 12.62
Quick Ratio 12.62
ITOS Yearly Current Assets VS Current LiabilitesITOS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 19.05% over the past year.
The Revenue has grown by 177.89% in the past year. This is a very strong growth!
Measured over the past years, ITOS shows a very negative growth in Revenue. The Revenue has been decreasing by -53.35% on average per year.
EPS 1Y (TTM)19.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.23%
Revenue 1Y (TTM)177.89%
Revenue growth 3Y-53.35%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 3.35% on average over the next years.
The Revenue is expected to decrease by -14.87% on average over the next years. This is quite bad
EPS Next Y-6.04%
EPS Next 2Y11.72%
EPS Next 3Y-1.96%
EPS Next 5Y3.35%
Revenue Next Year-83.85%
Revenue Next 2Y-53.88%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ITOS Yearly Revenue VS EstimatesITOS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2030 2031 2032 100M 200M 300M
ITOS Yearly EPS VS EstimatesITOS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ITOS. In the last year negative earnings were reported.
Also next year ITOS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ITOS Price Earnings VS Forward Price EarningsITOS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ITOS Per share dataITOS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.72%
EPS Next 3Y-1.96%

More info and screens

0

5. Dividend

5.1 Amount

ITOS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ITEOS THERAPEUTICS INC

NASDAQ:ITOS (6/13/2025, 8:11:50 PM)

After market: 10.17 0 (0%)

10.17

+0.19 (+1.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-28 2025-04-28/amc
Earnings (Next)08-06 2025-08-06/bmo
Inst Owners95.31%
Inst Owner Change8.02%
Ins Owners0.92%
Ins Owner Change4.71%
Market Cap389.21M
Analysts73.33
Price Target11.99 (17.9%)
Short Float %7.26%
Short Ratio2.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.35%
Min EPS beat(2)-15.79%
Max EPS beat(2)5.09%
EPS beat(4)3
Avg EPS beat(4)22.2%
Min EPS beat(4)-15.79%
Max EPS beat(4)82.99%
EPS beat(8)7
Avg EPS beat(8)25.01%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-53%
PT rev (3m)-52.93%
EPS NQ rev (1m)0%
EPS NQ rev (3m)9.94%
EPS NY rev (1m)14%
EPS NY rev (3m)14.09%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)10.54%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 11.12
P/FCF N/A
P/OCF N/A
P/B 0.66
P/tB 0.66
EV/EBITDA N/A
EPS(TTM)-3.06
EYN/A
EPS(NY)-2.5
Fwd EYN/A
FCF(TTM)-2.61
FCFYN/A
OCF(TTM)-2.57
OCFYN/A
SpS0.91
BVpS15.42
TBVpS15.42
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -19.57%
ROE -22.77%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-7.87%
ROA(5y)-2.39%
ROE(3y)-9.26%
ROE(5y)-0.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 133.93%
Cap/Sales 4.74%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.62
Quick Ratio 12.62
Altman-Z 2.45
F-Score4
WACC9.5%
ROIC/WACCN/A
Cap/Depr(3y)204.25%
Cap/Depr(5y)178.55%
Cap/Sales(3y)9.83%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.23%
EPS Next Y-6.04%
EPS Next 2Y11.72%
EPS Next 3Y-1.96%
EPS Next 5Y3.35%
Revenue 1Y (TTM)177.89%
Revenue growth 3Y-53.35%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-83.85%
Revenue Next 2Y-53.88%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y-5.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.22%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y6.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y5.37%
OCF growth 3YN/A
OCF growth 5YN/A